Alan C Cameron1, James Bogie1, Azmil H Abdul-Rahim2, Niaz Ahmed3,4, Michael Mazya3,4, Robert Mikulik5, Werner Hacke6, Kennedy R Lees1. 1. 1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 2. 2Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK. 3. 3Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. 5. International Clinical Research Centre, Neurology Department, St Anne's Hospital and Masaryk University, Brno, Czech Republic. 6. Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Abstract
INTRODUCTION: Thrombolysis usage in ischaemic stroke varies across sites. Divergent advice from professional guidelines and product labels may contribute. PATIENTS AND METHODS: We analysed SITS-International registry patients enrolled January 2010 through June 2016. We grouped sites into organisational tertiles by number of patients arriving ≤2.5 h and treated ≤3 h, percentage arriving ≤2.5 h and treated ≤3 h, and numbers treated ≤3 h. We assigned scores of 1-3 (lower/middle/upper) per variable and 2 for onsite thrombectomy. We classified sites as lower efficiency (summed scores 3-5), medium efficiency (6-8) or higher efficiency (9-11). Sites were also grouped by adherence with European product label and ESO guideline: 'label adherent' (>95% on-label), 'guideline adherent' (≥5% off-label, ≥95% on-guideline) or 'guideline non-adherent' (>5% off-guideline). We cross-tabulated site-efficiency and adherence. We estimated the potential benefit of universally selecting by ESO guidance, using onset-to-treatment time-specific numbers needed to treat for day 90 mRS 0-1. RESULTS: A total of 56,689 patients at 597 sites were included: 163 sites were higher efficiency, 204 medium efficiency and 230 lower efficiency. Fifty-six sites were 'label adherent', 204 'guideline adherent' and 337 'guideline non-adherent'. There were strong associations between site-efficiency and adherence (P < 0.001). Almost all 'label adherent' sites (55, 98%) were lower efficiency. If all patients were treated by ESO guidelines, an additional 17,031 would receive alteplase, which translates into 1922 more patients with favourable three-month outcomes. DISCUSSION: Adherence with product labels is highest in lower efficiency sites. Closer alignment with professional guidelines would increase patients treated and favourable outcomes. CONCLUSION: Product labels should be revised to allow treatment of patients ≤4.5 h from onset and aged ≥80 years.
INTRODUCTION: Thrombolysis usage in ischaemic stroke varies across sites. Divergent advice from professional guidelines and product labels may contribute. PATIENTS AND METHODS: We analysed SITS-International registry patients enrolled January 2010 through June 2016. We grouped sites into organisational tertiles by number of patients arriving ≤2.5 h and treated ≤3 h, percentage arriving ≤2.5 h and treated ≤3 h, and numbers treated ≤3 h. We assigned scores of 1-3 (lower/middle/upper) per variable and 2 for onsite thrombectomy. We classified sites as lower efficiency (summed scores 3-5), medium efficiency (6-8) or higher efficiency (9-11). Sites were also grouped by adherence with European product label and ESO guideline: 'label adherent' (>95% on-label), 'guideline adherent' (≥5% off-label, ≥95% on-guideline) or 'guideline non-adherent' (>5% off-guideline). We cross-tabulated site-efficiency and adherence. We estimated the potential benefit of universally selecting by ESO guidance, using onset-to-treatment time-specific numbers needed to treat for day 90 mRS 0-1. RESULTS: A total of 56,689 patients at 597 sites were included: 163 sites were higher efficiency, 204 medium efficiency and 230 lower efficiency. Fifty-six sites were 'label adherent', 204 'guideline adherent' and 337 'guideline non-adherent'. There were strong associations between site-efficiency and adherence (P < 0.001). Almost all 'label adherent' sites (55, 98%) were lower efficiency. If all patients were treated by ESO guidelines, an additional 17,031 would receive alteplase, which translates into 1922 more patients with favourable three-month outcomes. DISCUSSION: Adherence with product labels is highest in lower efficiency sites. Closer alignment with professional guidelines would increase patients treated and favourable outcomes. CONCLUSION: Product labels should be revised to allow treatment of patients ≤4.5 h from onset and aged ≥80 years.
Entities:
Keywords:
Alteplase; product label; professional guideline; thrombolysis
Authors: Elena Meseguer; Julien Labreuche; Jeam Marc Olivot; Halim Abboud; Philippa C Lavallee; Olivier Simon; Lucie Cabrejo; Amaya Echeverria; Isabelle F Klein; Mikael Mazighi; Pierre Amarenco Journal: Age Ageing Date: 2007-12-03 Impact factor: 10.668
Authors: Kennedy R Lees; Erich Bluhmki; Rüdiger von Kummer; Thomas G Brott; Danilo Toni; James C Grotta; Gregory W Albers; Markku Kaste; John R Marler; Scott A Hamilton; Barbara C Tilley; Stephen M Davis; Geoffrey A Donnan; Werner Hacke; Kathryn Allen; Jochen Mau; Dieter Meier; Gregory del Zoppo; D A De Silva; K S Butcher; M W Parsons; P A Barber; C Levi; C Bladin; G Byrnes Journal: Lancet Date: 2010-05-15 Impact factor: 79.321
Authors: H Christian Schumacher; Brian T Bateman; Bernadette Boden-Albala; Mitchell F Berman; J P Mohr; Ralph L Sacco; John Pile-Spellman Journal: Ann Emerg Med Date: 2007-05-03 Impact factor: 5.721
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Werner Hacke; Mónica Millán; Keith Muir; Risto O Roine; Danilo Toni; Kennedy R Lees Journal: Lancet Date: 2008-09-12 Impact factor: 79.321
Authors: Louise E Craig; Sandy Middleton; Helen Hamilton; Fern Cudlip; Victoria Swatzell; Andrei V Alexandrov; Elizabeth Lightbody; Dame Caroline Watkins; Sheeba Philip; Dominique A Cadilhac; Elizabeth McInnes; Simeon Dale; Anne W Alexandrov Journal: Interv Neurol Date: 2018-09-25